Last updated: September 8, 2026
Bisoprolol fumarate and hydrochlorothiazide is a mature fixed-dose antihypertensive combination sold in the United States under the brand Ziac and through multiple generic suppliers. Its commercial profile is defined by low-cost generic competition, limited differentiation, and the absence of meaningful biologic or formulation barriers. Product-specific revenue is not publicly reported by major manufacturers, but the combination is best characterized as a low-growth, price-competitive generic market with stable prescription demand.
What is bisoprolol fumarate and hydrochlorothiazide?
Bisoprolol fumarate and hydrochlorothiazide combines a cardioselective beta blocker with a thiazide diuretic. Bisoprolol lowers heart rate and sympathetic activity, while hydrochlorothiazide promotes sodium and fluid excretion. The product is approved for hypertension when treatment with either component alone does not provide adequate control.[1]
| Attribute |
Description |
| Active ingredients |
Bisoprolol fumarate and hydrochlorothiazide |
| Drug class |
Beta blocker and thiazide diuretic |
| Primary indication |
Hypertension |
| Original U.S. brand |
Ziac |
| Dosage form |
Immediate-release oral tablet |
| Common strengths |
2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg |
| Regulatory pathway |
New drug application followed by abbreviated new drug applications |
| Biosimilar relevance |
None; this is a synthetic small-molecule product |
| Current market structure |
Primarily generic |
| Commercial maturity |
Mature and low growth |
The combination is generally used when a prescriber wants to simplify treatment or maintain complementary blood-pressure effects in one tablet. It does not have a differentiated delivery system, device component, or complex manufacturing process.
When does bisoprolol fumarate and hydrochlorothiazide lose exclusivity?
The original brand exclusivity for Ziac has expired. The product has been exposed to generic competition for many years, and the market no longer depends on a single originator supplier.
U.S. regulatory exclusivity for a product of this age is no longer the main commercial constraint. The relevant competitive issues are generic approval, supply reliability, wholesaler contracting, reimbursement, and pharmacy substitution.
What is the FDA regulatory status of Ziac?
Ziac was approved as a fixed-dose combination for hypertension. FDA-approved generic versions may rely on the reference product through the abbreviated new drug application pathway, provided they demonstrate pharmaceutical equivalence and bioequivalence.[1][2]
The combination is a conventional immediate-release tablet. It does not require the clinical development or interchangeability framework associated with biologic products. FDA approval is therefore primarily an equivalence and manufacturing-compliance question.
What is the Orange Book status of bisoprolol and hydrochlorothiazide?
The Orange Book is the relevant U.S. source for listed patents, exclusivity, therapeutic equivalence ratings, and reference products.[2] For this mature combination, the commercial significance of Orange Book protection is limited because the original brand patent and exclusivity period have expired.
A current Orange Book review should be used for transaction or litigation decisions because listed products, approved manufacturers, and patent records can change. No active, commercially material brand patent position is generally associated with the legacy Ziac product.
How many patents cover bisoprolol fumarate and hydrochlorothiazide?
The original combination was protected by legacy composition, formulation, and product patents, but those rights have expired or ceased to create a meaningful barrier to routine generic entry.
The patent estate is weak from a market-exclusivity perspective for four reasons:
- The active ingredients are longstanding small molecules.
- The dosage form is an immediate-release tablet.
- The combination has no complex device or extended-release architecture.
- Generic manufacturers can generally compete through standard abbreviated applications.
Potentially relevant patent categories include:
| Patent category |
Commercial relevance |
| Combination-product claims |
Historically relevant, now generally expired |
| Tablet formulation claims |
Limited protection if claims cover conventional excipients or release characteristics |
| Manufacturing claims |
Could affect a particular process but would not normally block all generic supply |
| Method-of-use claims |
Limited value for a broad hypertension indication |
| Salt or polymorph claims |
Low relevance where the marketed active and established manufacturing routes are well known |
| Packaging or labeling claims |
Usually insufficient to preserve broad product exclusivity |
Are there Paragraph IV challenges for bisoprolol fumarate and hydrochlorothiazide?
Paragraph IV litigation is not a central current risk for this product because generic entry occurred long ago and the original exclusivity period has ended. A Paragraph IV certification is most commercially important when a generic applicant challenges an unexpired Orange Book patent before market entry.[3]
For bisoprolol fumarate and hydrochlorothiazide, competitive entry is more likely to involve abbreviated applications, manufacturing supplements, product discontinuations, and supplier changes than new patent litigation.
No material current Paragraph IV campaign is widely associated with the legacy Ziac market.
What formulations are protected by bisoprolol fumarate and hydrochlorothiazide patents?
The marketed product is an immediate-release tablet. It is not a long-acting depot, transdermal system, inhaled formulation, or complex oral delivery technology.
Formulation-related commercial protection is therefore limited. A manufacturer may obtain process or formulation patents covering a particular excipient system, tablet-coating method, impurity-control process, or manufacturing sequence. Those rights would usually protect a supplier’s process rather than prevent market entry by all competitors.
The practical formulation risks are manufacturing quality and supply continuity, not an enduring patent moat. Relevant quality attributes include dose uniformity, dissolution, stability, impurity control, and consistency of the bisoprolol-hydrochlorothiazide blend.
What is the competitive landscape for bisoprolol fumarate and hydrochlorothiazide?
The product competes with both substitute fixed-dose combinations and separate-component therapy.
Direct competitors
Direct competition comes from generic versions of the same bisoprolol-hydrochlorothiazide combination. Suppliers compete on:
- Wholesale acquisition price
- Medicaid and commercial reimbursement
- Pharmacy benefit manager access
- National wholesaler supply
- Authorized generic arrangements
- Product availability by strength
- Manufacturing reliability
Therapeutic substitutes
Physicians can substitute other antihypertensive combinations, including:
| Alternative |
Competitive effect |
| Bisoprolol alone |
Avoids diuretic exposure and permits independent titration |
| Hydrochlorothiazide with another beta blocker |
Similar beta-blocker/diuretic strategy |
| ACE inhibitor/thiazide combinations |
Common alternative, particularly in broad hypertension treatment |
| ARB/thiazide combinations |
Frequently used when ACE inhibitors are not tolerated |
| Calcium-channel blocker combinations |
Compete for first-line and add-on treatment |
| Separate bisoprolol and hydrochlorothiazide tablets |
Reduces dependence on the fixed-dose product |
Guideline-driven prescribing also limits the long-term growth potential of this combination. Hypertension treatment increasingly emphasizes individualized therapy, comorbidities, renal function, cardiovascular risk, and adherence rather than a single legacy combination brand.[4]
How strong is the patent estate for bisoprolol fumarate and hydrochlorothiazide?
The patent estate is commercially weak. It may have historical documentation value, but it does not provide a credible platform for premium pricing or market exclusivity.
| Factor |
Assessment |
| Active-ingredient novelty |
Low |
| Remaining composition patents |
Limited or expired |
| Formulation complexity |
Low |
| Manufacturing barriers |
Moderate at the individual-facility level |
| Regulatory barrier to generic entry |
Low to moderate |
| Substitution risk |
High |
| Pricing power |
Low |
| Litigation leverage |
Low |
| Lifecycle-management potential |
Low |
A new patent covering a narrow manufacturing improvement could have value for a supplier with a cost advantage, but it would not materially change the structure of the overall market unless the claim covered a commercially necessary process.
What is the financial trajectory for bisoprolol fumarate and hydrochlorothiazide?
The financial trajectory is typical of a mature generic combination:
- Brand growth during the protected period.
- Rapid price and share erosion after generic entry.
- Stabilization at a low unit-price base.
- Periodic price increases or shortages when supplier concentration rises.
- Long-term decline in nominal value as more suppliers enter or prescribing shifts to alternative regimens.
Product-level revenue is not separately disclosed in the public filings of the major generic manufacturers. The combination is generally included within broader cardiovascular, generic, or U.S. pharmaceuticals revenue categories. That limits precise calculation of annual sales, market share, and gross margin for the individual product.
What drives revenue?
Revenue depends more on supply and contracting than on clinical differentiation. The principal variables are:
- Number of approved generic suppliers
- Active supplier count in each strength
- Pharmacy benefit manager coverage
- Government reimbursement
- Shortage conditions
- API and excipient costs
- Manufacturing-site compliance
- Retail prescription volume
- Conversion to alternative antihypertensive combinations
A mature generic product can produce attractive cash flow for a low-cost manufacturer when production is efficient and competition is temporarily constrained. It usually cannot support sustained premium pricing without a shortage, a supply disruption, or a specialized contract.
Margin outlook
Margins are likely to remain compressed under normal supply conditions. The principal margin risks are:
- Price competition among multiple ANDA holders
- Low-cost international manufacturing
- FDA warning letters or remediation costs
- API sourcing disruptions
- Product recalls
- Contract loss with a major wholesaler or pharmacy customer
- Reduced prescription volume from therapeutic substitution
Margins can temporarily improve during supply shortages, but shortage-driven pricing is volatile and may attract additional entrants or regulatory scrutiny.
What generic launch scenarios exist?
Base case
Generic supply remains available from multiple manufacturers. Prices decline gradually, and demand remains stable but modest. The product continues as a low-value maintenance medicine with limited commercial investment.
Downside case
Several suppliers exit because of low margins, manufacturing problems, or API constraints. A shortage develops, but the resulting price increase is offset by lost volume, substitution, and regulatory pressure.
Upside case
A manufacturer obtains a reliable low-cost supply position, secures a major payer or pharmacy contract, and benefits from competitor exits. The upside is usually share gain and improved utilization, not category growth.
Strategic-risk case
Prescribers increasingly use ARB/thiazide, ACE inhibitor/thiazide, or non-diuretic regimens. Fixed-dose bisoprolol/hydrochlorothiazide prescriptions decline even if overall hypertension treatment expands.
What patent litigation and settlement agreements affect the product?
No major current litigation or settlement structure is generally associated with the mature bisoprolol-hydrochlorothiazide combination. The most important historical litigation would have involved generic entry against legacy brand patents. Those disputes no longer define the market.
For diligence, the more relevant legal records are:
- FDA Orange Book listings
- ANDA approvals
- FDA inspection and warning-letter history
- Product-liability claims
- Antitrust cases involving generic price coordination
- Supply and distribution contracts
- Recall and shortage records
Patent settlements have limited current value where the relevant patents have expired and multiple generic suppliers are already active.
How does bisoprolol fumarate and hydrochlorothiazide compare with competing antihypertensive combinations?
| Product class |
Patent risk |
Growth outlook |
Pricing power |
Main commercial advantage |
| Bisoprolol/hydrochlorothiazide |
Low |
Low |
Low |
Established combination and familiar dosing |
| ACE inhibitor/thiazide |
Low to moderate |
Low to moderate |
Low |
Broad clinical use |
| ARB/thiazide |
Low to moderate |
Moderate |
Low to moderate |
Tolerability and common guideline use |
| Beta blocker alone |
Low |
Low |
Low |
Flexible titration |
| Calcium-channel blocker combination |
Low to moderate |
Moderate |
Low to moderate |
Broad therapeutic substitution |
| Newer branded antihypertensive products |
Variable |
Variable |
Higher if protected |
Differentiated formulation or indication |
The combination is less commercially attractive than products with patent-protected delivery systems, cardiovascular outcome differentiation, or a branded adherence platform.
What geographic markets matter?
The United States is a mature generic market. Europe, Canada, Australia, and other developed markets also have longstanding generic competition, although brand names, reimbursement systems, reference pricing, and substitution rules differ.
Emerging markets may have higher unit growth, but lower prices and fragmented distribution reduce the value of a single-country opportunity. Local registration, manufacturing requirements, import controls, and tender pricing often determine commercial success.
For licensing or acquisition purposes, geographic value is more likely to reside in manufacturing scale, regulatory approvals, and distribution access than in patent rights.
Key Takeaways
- Bisoprolol fumarate and hydrochlorothiazide is a mature fixed-dose hypertension product.
- Ziac exclusivity has expired, and the market is primarily generic.
- No meaningful biosimilar risk applies because both active ingredients are synthetic small molecules.
- The Orange Book and ANDA landscape matter more than active brand patent litigation.
- The formulation is a conventional immediate-release tablet with limited technical differentiation.
- Product-specific revenue is not publicly reported by major manufacturers.
- Financial performance depends on generic volume, supplier concentration, contracting, and manufacturing reliability.
- The patent estate is weak, with low capacity to support premium pricing or prevent substitution.
- The main commercial risks are price erosion, supplier exits, shortages, recalls, and migration to other antihypertensive combinations.
- The most credible upside is share capture through low-cost, reliable supply rather than category expansion.
FAQs About Bisoprolol Fumarate and Hydrochlorothiazide
Is bisoprolol fumarate and hydrochlorothiazide still patent protected?
The original product’s broad commercial exclusivity has expired. Narrow process or formulation patents could exist for individual manufacturers, but they do not generally create a broad barrier to generic competition.
Is Ziac still a branded growth product?
No. Ziac is a legacy brand, and the commercial market is primarily supplied by generic manufacturers. Any remaining branded demand is limited relative to generic volume.
Can a generic manufacturer launch bisoprolol and hydrochlorothiazide without clinical trials?
A manufacturer generally seeks FDA approval through an ANDA by demonstrating pharmaceutical equivalence and bioequivalence to the reference product. Full efficacy trials are typically not required for each generic applicant.[2]
Does bisoprolol and hydrochlorothiazide have shortage-driven revenue potential?
Temporary revenue increases can occur during supply disruptions, but shortage-driven gains are unstable. They may be followed by new market entrants, therapeutic substitution, or regulatory intervention.
Is the combination attractive for pharmaceutical licensing?
Its licensing value is usually limited. The strongest opportunities are linked to manufacturing cost, reliable API access, regulatory approvals in underserved markets, or distribution contracts rather than patent exclusivity.
References
-
U.S. Food and Drug Administration. (n.d.). Ziac (bisoprolol fumarate and hydrochlorothiazide) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.
-
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., Williamson, J. D., & Wright, J. T. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115.
